-
公开(公告)号：US20140154259A1
公开(公告)日：2014-06-05
申请号：US14021547
申请日：2013-09-09
IPC分类号： C07K16/28
CPC分类号： C07K16/2842 , A61K2039/505 , C07K16/2821 , C07K16/2839 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
摘要翻译： 公开了治疗炎症性疾病的方法，特别是治疗关节炎。 该方法包括施用能够结合VLA-1表位的功能阻断抗体。
-
公开(公告)号：US20140147432A1
公开(公告)日：2014-05-29
申请号：US14105224
申请日：2013-12-13
申请人： Stephane Bancel , Tirtha Chakraborty , Antonin de Fougerolles , Susan Whoriskey , Sayda M. Elbashir
发明人： Stephane Bancel , Tirtha Chakraborty , Antonin de Fougerolles , Susan Whoriskey , Sayda M. Elbashir
IPC分类号： C12N9/64
CPC分类号： A61K48/0066 , A61K9/1271 , A61K9/145 , A61K9/5123 , A61K9/5146 , A61K9/5153 , A61K31/7115 , A61K38/00 , A61K38/17 , A61K38/177 , A61K38/1816 , A61K38/1891 , A61K38/191 , A61K38/193 , A61K38/212 , A61K38/45 , A61K38/4846 , A61K47/543 , A61K48/0033 , A61K48/005 , A61K48/0075 , C07K14/005 , C07K14/435 , C07K14/47 , C07K14/4705 , C07K14/4713 , C07K14/485 , C07K14/505 , C07K14/515 , C07K14/525 , C07K14/535 , C07K14/56 , C07K14/62 , C07K14/705 , C07K16/00 , C12N9/1051 , C12N9/16 , C12N9/2402 , C12N9/2445 , C12N9/644 , C12N9/6451 , C12N9/88 , C12N9/93 , C12N15/11 , C12N15/52 , C12N15/85 , C12N15/87 , C12P13/04 , C12P21/00 , C12P21/005 , C12Y304/21022 , C12Y603/02019
摘要： The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
-
3.发明申请MODIFIED POLYNUCLEOTIDES ENCODING SIAH E3 UBIQUITIN PROTEIN LIGASE 1 有权修饰的多核苷酸编码SIAH E3 UBIQUITIN蛋白质1公开(公告)号：US20140141068A1
公开(公告)日：2014-05-22
申请号：US14107105
申请日：2013-12-16
IPC分类号： C07K14/47
CPC分类号： A61K48/0066 , A61K9/1271 , A61K9/145 , A61K9/5123 , A61K9/5146 , A61K9/5153 , A61K31/7115 , A61K38/00 , A61K38/17 , A61K38/177 , A61K38/1816 , A61K38/1891 , A61K38/191 , A61K38/193 , A61K38/212 , A61K38/45 , A61K38/4846 , A61K47/543 , A61K48/0033 , A61K48/005 , A61K48/0075 , C07K14/005 , C07K14/435 , C07K14/47 , C07K14/4705 , C07K14/4713 , C07K14/485 , C07K14/505 , C07K14/515 , C07K14/525 , C07K14/535 , C07K14/56 , C07K14/62 , C07K14/705 , C07K16/00 , C12N9/1051 , C12N9/16 , C12N9/2402 , C12N9/2445 , C12N9/644 , C12N9/6451 , C12N9/88 , C12N9/93 , C12N15/11 , C12N15/52 , C12N15/85 , C12N15/87 , C12P13/04 , C12P21/00 , C12P21/005 , C12Y304/21022 , C12Y603/02019
摘要： The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
摘要翻译： 本发明涉及用于制备，制造和治疗使用肿瘤学相关多核苷酸，肿瘤学相关的初级转录物和肿瘤相关的mmRNA分子的组合物和方法。
-
公开(公告)号：US08557240B2
公开(公告)日：2013-10-15
申请号：US13296778
申请日：2011-11-15
IPC分类号： A61K39/395
CPC分类号： C07K16/2842 , A61K2039/505 , C07K16/2821 , C07K16/2839 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76
摘要： A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
-
5.发明授权Compositions and methods for inhibiting expression of a gene from the ebola virus 有权用于抑制基因从埃博拉病毒表达的组合物和方法公开(公告)号：US08354390B2
公开(公告)日：2013-01-15
申请号：US13093681
申请日：2011-04-25
申请人： Sina Bavari , Kelly Lyn Warfield , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Antonin de Fougerolles
发明人： Sina Bavari , Kelly Lyn Warfield , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Antonin de Fougerolles
CPC分类号： C12N15/1131 , C07H21/02 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3521 , C12N2310/3531
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
摘要翻译： 本发明涉及用于抑制埃博拉病毒基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US20120251618A1
公开(公告)日：2012-10-04
申请号：US13437034
申请日：2012-04-02
申请人： Jason P. Schrum , Noubar B. Afeyan , Gregory J. Sieczkiewicz , Stephane Bancel , Antonin de Fougerolles , Sayda M. Elbashir
发明人： Jason P. Schrum , Noubar B. Afeyan , Gregory J. Sieczkiewicz , Stephane Bancel , Antonin de Fougerolles , Sayda M. Elbashir
IPC分类号： A61K31/7105 , C07H21/02 , A61K9/127
CPC分类号： A61K47/18 , A61K31/7088 , A61K31/7115 , A61K38/193 , A61K38/4846 , A61K47/22 , A61K47/28 , A61K48/00 , C07K14/535 , C12N9/644 , C12N15/67 , C12N15/87 , C12N2310/335
摘要： Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the delivery of biological moieties, and are useful for production of proteins.
摘要翻译： 提供了将生物学部分如修饰的核酸递送到细胞中以调节蛋白质表达的制剂，组合物和方法。 这样的组合物和方法包括递送生物部分，并且可用于生产蛋白质。
-
公开(公告)号：US20120208860A1
公开(公告)日：2012-08-16
申请号：US12970673
申请日：2010-12-16
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521 , C12Y304/21021
摘要： The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
摘要翻译： 本发明涉及用于抑制因子VII基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US20120115934A1
公开(公告)日：2012-05-10
申请号：US13355930
申请日：2012-01-23
申请人： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
发明人： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
摘要翻译： 本公开涉及可用于使用治疗有效量治疗β-ENAC相关疾病如囊性纤维化，1型假性醛固酮增多症（1例（PHA1），跛行综合征，高血压，碱中毒，低钾血症和肥胖相关性高血压）的方法中的RNAi剂 的RNAi试剂到β-ENaC。
-
公开(公告)号：US20120115933A1
公开(公告)日：2012-05-10
申请号：US13355903
申请日：2012-01-23
申请人： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
发明人： Antonin DE FOUGEROLLES , John L. DIENER , Emma HICKMAN , Gregory HINKLE , Stuart MILSTEIN , Anne-Marie PULICHINO , Andrew SPRAGUE
CPC分类号： C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
摘要： The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
公开(公告)号：US20110224282A1
公开(公告)日：2011-09-15
申请号：US13043228
申请日：2011-03-08
申请人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
发明人： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
IPC分类号： A61K31/713 , C07H21/02 , A61P27/02 , C12N5/071 , C12N5/09
CPC分类号： C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
摘要： The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
摘要翻译： 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.085 秒)
